CAR T-Cell Therapy: Who Is a Candidate? | Myeloma in a Minute (https://www.myeloma.org/videos/car-t-cell-therapy-who-candidate-myeloma-minute)
CAR T-Cell Therapy: Who Is a Candidate? | Myeloma in a Minute
Could you be a candidate for CAR T-cell therapy to treat multiple myeloma?
In this quick expert explainer video, Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO discusses who may be eligible for CAR T-cell therapy, including treatment history, disease characteristics, and overall health considerations.
Learn how prior myeloma treatments, organ function, remission status, and disease activity can affect CAR T-cell therapy eligibility. Whether you're newly diagnosed, experiencing relapse, exploring treatment options, or supporting a loved one with multiple myeloma, this video can help you better understand when CAR T-cell therapy may be considered.
Have a question that needs more personalized support? Call us! We’re here for you. The IMF’s InfoLine is available to answer your myeloma-related questions and concerns. Call us at 1-818-487-7455, email us at [email protected] (mailto:[email protected]), or schedule your call at a time that works best for you at www.myeloma.org/infoline (https://www.myeloma.org/infoline).
Beth Faiman:
You might have heard of CAR T-cell therapy, but who's a candidate? Hi, my name is Beth Faiman. I am on the International Myeloma Foundation's Nurse Leadership Board, and I'm here to talk to you about CAR T-cell therapy in a minute or less.
So, CAR T-cell therapy is a very innovative therapy that has proved to be very effective for many patients with myeloma. You can have CAR T-cell therapy if you've had one prior line of therapy including with bortezomib or Velcade and lenalidomide or an immunomodulatory drug. It's really important to know if you're a candidate or not and then seek the information. Other important factors are your organ function, kidney, liver, heart in order to withstand the procedure, and also your disease characteristics. If you have rapidly dividing myeloma cells and active myeloma, you might not do as well, so we need to get you in remission first.
So if you are wondering if you're a candidate for CAR T-cell therapy, talk to your healthcare provider. Seek out a CAR T-cell therapy center and have that discussion to find out if CAR T-cell therapy might be right for you.
Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO
Cleveland Clinic Taussig Cancer Institute
IMF Nurse Leadership Board Member
Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO, has become an exemplary leader in bringing critical knowledge of cancer nursing to clinical providers — locally, nationally, and internationally. As a founding member of the International Myeloma Foundation Nurse Leadership Board (NLB) and practicing clinician, she demonstrates enthusiasm for continuous learning by conducting innovative research and demonstrates the importance of using and integrating new medical knowledge within nursing practices. In 2023, Faiman was given the NP/PA Educator of Distinction Award in Multiple Myeloma and in 2022, Faiman was named the Top NP in Hematology/Oncology and inducted as an inaugural Fellow of Advanced Practice in Oncology (FAPO) awarded by the Advanced Practitioner Society for Hematology and Oncology (APSHO). Faiman is a Distinguished Fellow in the American Academy of Nursing (FAAN). She is the current Editor-in-Chief of Journal of the Advanced Practitioner in Oncology. She remains an active author, presenter, mentor, and educator on the topics of hematology, oncology and supportive cancer care.
Faiman received her Bachelor of Science in Nursing degree from Ursuline Academy (1996), a Master of Science in Nursing at Kent State University (2002), and a PhD in clinical research from Case Western Reserve University (2014). Faiman is an adult nurse practitioner in the Department of Hematology/Oncology at the Cleveland Clinic in Ohio, and a clinical member of the Case Comprehensive Cancer Center under the Cancer Prevention, Control and Population Research Program. She has edited several books and authored many chapters and papers, including Editor of the 3rd Edition of the Multiple Myeloma Textbook for Nurses (2021), and both Editions of the Blood and Marrow Certification Manual for Nurses (2017, 2023), by ONS publishing. She previously held appointments on the American Board of Internal Medicine and American Society of Hematology.
Tag #AsktheIMF to Ask Your Questions on Social Media!
Facebook: @myeloma (https://www.facebook.com/myeloma) | Instagram: @IMFmyeloma (https://www.instagram.com/imfmyeloma/) | Twitter/X: @IMFmyeloma (https://www.twitter.com/IMFmyeloma)
See all of our social media channels at linktr.ee/myeloma (https://linktr.ee/myeloma)